Viking Therapeutics (VKTX) Q3 2025 earnings review
Execution Machine: Clinical Velocity Accelerates While Burn Rate Quadruples
Viking is aggressively converting its cash pile into clinical speed. The company delivered a flawless operational quarter: the massive 4,500-patient VANQUISH-1 Phase 3 trial enrolled ahead of schedule, and Phase 2 oral data (12.2% weight loss) solidifies a best-in-class potential. However, the cost of speed is evident on the P&L—R&D expenses quadrupled YoY to nearly $90M. With $715M in cash remaining, Viking is fully funded through these pivotal readouts, but the era of low-cost development is definitively over.
🐂 Bull Case
Enrollment speed is a proxy for market demand and operational competence. Finishing enrollment for VANQUISH-1 (4,500 patients) ahead of schedule in a crowded obesity trial landscape is a major signal of investigator enthusiasm and execution capability.
Phase 2 oral data showed up to 12.2% weight loss at 13 weeks. This is comparable to competitor injectables and superior to existing orals. If replicated in Phase 3 (starting 26Q3), Viking holds the 'Holy Grail' of obesity: a highly effective pill.
🐻 Bear Case
Operating loss widened to $98.5M from $36.5M a year ago. At the current run rate (~$360M annualized and growing), the $715M cash pile provides a shorter runway than previously modeled, potentially necessitating a raise before commercialization.
The IND filing for the novel Amylin program, previously targeted for 'later in 2025,' has slipped slightly to Q1 2026. While minor, it delays the diversification of the pipeline beyond the GLP-1/GIP franchise.
⚖️ Verdict: 🟢🟢
Strong Bullish. Viking is hitting every major milestone. The explosion in R&D spend is the 'good kind' of expense—direct investment in a de-risked asset moving to registration. The rapid enrollment and stellar oral data outweigh concerns about the burn rate.
Key Themes
Oral VK2735: Best-in-Class Potential confirmed
Viking released Phase 2 oral data showing up to 12.2% weight loss at 13 weeks. This is a critical differentiator. Most competitors struggle to balance efficacy with tolerability in oral formulations. Viking's transition to Phase 3 in Q3 2026 puts them in prime position to capture the needle-averse segment of the market.
Maintenance Dosing Strategy
Viking is actively differentiating through dosing flexibility. The newly initiated maintenance study explores monthly subcutaneous and weekly/daily oral options. This directly addresses the 'persistence' problem in obesity treatment—payers and patients want options to maintain weight loss without weekly injections forever.
Hyper-Scaling R&D Expenses
Accelerating. R&D expense surged 295% YoY to $90M. This reflects the massive logistical undertaking of Phase 3 (manufacturing, CROs, sites). While necessary, it drastically alters the company's financial profile from a lean biotech to a heavy spender.
Regulatory Uncertainty for Oral Program
Management plans an End-of-Phase 2 meeting with the FDA to discuss the oral program. There is a risk the FDA could require a Phase 2b study before Phase 3, which would delay the timeline significantly. Management guidance assumes a direct move to Phase 3 in Q3 2026.
NASH/Rare Disease Deprioritization
Stable. Viking continues to signal that VK2809 (NASH) and VK0214 (X-ALD) are assets for partnering rather than internal focus. Despite positive data, no deal has materialized, leaving these assets in limbo while cash is funneled to obesity.
Other KPIs
Decelerating. Down from $808M in Q2 and $903M at YE24. Burn rate in Q3 alone was ~$93M. At this pace, the company has roughly 7-8 quarters of runway, effectively covering the VANQUISH readouts but likely requiring capital formation before commercial launch.
Accelerating. Loss widened significantly from $35.4M in Q4'24 and $65.6M in Q2'25. This is purely a function of clinical activity; G&A remains relatively disciplined ($8.6M), proving the spend is going into the science, not overhead.
Guidance
Decelerating. Previously guided for 'later in 2025' or 'Q4 2025'. The timeline has slipped by a quarter. This is the next leg of the pipeline stool, so timing matters.
New Guidance. Management explicitly targeted Q3 2026 for the start of the oral Phase 3 program, contingent on FDA feedback. This sets a clear clock for the next major value inflection.
Stable/On-Track. The Type 2 Diabetes study (1,100 patients) is following the rapid pace of VANQUISH-1. Completion here sets the stage for a synchronized data readout likely in 2027.
New Guidance. Data from the maintenance dosing study (SubQ vs Oral) is expected in Q3 2026. This data will be crucial for payer discussions and commercial differentiation.
Key Questions
Manufacturing Scale-Up
With Phase 3 enrollment moving faster than expected, is commercial manufacturing capacity (both API and auto-injectors) locked in to support a potential launch immediately following approval, or is there a risk of a 'supply gap'?
Oral Phase 3 Design
Will the Phase 3 oral trial be a head-to-head against oral semaglutide (Rybelsus) or placebo-controlled? A head-to-head win on tolerability and efficacy would be a massive commercial catalyst.
Partnering Stagnation
VK2809 (NASH) data was positive and 'best-in-class' for biopsy-confirmed resolution. Why has a partnership deal not materialized after several quarters? Is the biopsy requirement for future trials a deal-breaker for potential partners?